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1. Introduction 
Gangliosides are sialic acid-containing glycolipids that are mainly localized in the outer 
leaflet of the plasma membrane of vertebrate cells and are involved in diverse physiological 
functions such as cell growth, differentiation, and cell-cell recognition(Hakomori, 1990). In 
the nervous system, gangliosides are highly expressed in neurons and are implicated in 
neurite outgrowth, synaptogenesis, and modulation of synaptic transmission(Posse de 
Chaves and Sipione, 2010). In this context, gangliosides have been proposed to act as co-
receptors for growth factors (e.g. fibroblast growth factor) and neurotransmitters (e.g. 
serotonin)(Posse de Chaves and Sipione, 2010). Gangliosides are also localized in some glial 
cells in both gray and white matter, thereby affecting myelin sheath stability through 
association with myelin-associated glycoprotein(Schnaar, 2010). 
There is immense large body of knowledge on the biosynthesis and catabolism of 
gangliosides. In brief, gangliosides are synthesized by sequential addition of single sugars 
catalyzed by multiple glycosyltransferases (Fig. 1). The profiles of ganglioside 
components in neurons and glia are developmently regulated(Yamamoto et al., 1996; Yu 
et al., 2009). For instance, the dominant pathway in neurons during the neonate stage is 
pathway “a”, which starts from GM3 and leads to GT1a via GM1 and GD1a. In adult 
human brain, four gangliosides (GM1, GD1a, GD1b and GT1b) are mainly produced, and 
these make up the majority (> 66 %) of gangliosides in the brain(Ando et al., 1978). It is 
also believed that each ganglioside has a specific function in the brain and is not merely 
an intermediate metabolite in the synthesis of more prevalent gangliosides(Yamamoto et 
al., 1996; Yu et al., 2009). 
Gangliosides are in turn degraded by various lysosomal hydrolases with the aid of 
sphingolipid activator proteins. If a specific hydrolase required for this process is partially 
or totally missing due to a genetic deficit, gangliosides accumulate in the lysosomes and 
result in lysosomal dysfunction, which manifests as a lysosomal storage diseases 
(LSD)(Jalanko and Braulke, 2009; Vitner et al., 2010). Furthermore, it has been shown that 
gangliosides are secondarily upregulated in many other sphingolipidoses(Vitner et al., 
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2010). In this review, we do not describe the details of LSDs, but we refer to the linkage of 
LSDs and neurodegenerative diseases in a later section. 
 
 
Fig. 1. Schemes of ganglioside synthesis 
Synthesis is depicted starting with lactosylceramide (LacCer). GalNAc-T, 
GA2/GM2/GD2/GT2 synthase; GalT-II, GA1/GM1/GD1b/GT1c synthase; ST-IV, 
GM1b/GD1a/GT1b/GQ1c synthase; ST-V, GD1c/GT1a/GQ1b/GP1c synthase; ST-V, 
GD1a/GT1a/GQ1b/GP1c synthase. 
Beyond LSDs, gangliosides have been implicated in various pathologies. In particular, 
evidence has accumulated to suggest a role of gangliosides in age-associated 
neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
To date, the effect of gangliosides on the pathogenesis of AD is a controversial issue. Many 
studies suggest that gangliosides stimulate fibrillogenesis of amyloid -protein (A) in the 
early stage of pathogenesis(Yanagisawa et al., 1995), whereas others have shown that GM1 
ganglioside has a beneficial effect on early onset AD, presumably through the sequestration 
of A(Matsuoka et al., 2003; Svennerholm, 1994). A limited number of reports also suggest 
that gangliosides are protective against the pathogenesis of PD(Hadjiconstantinou et al., 
1986; Wei et al., 2009b). With this background, the main objective of this review is to outline 
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what is known about the roles of gangliosides in neurodegenerative diseases, including AD 
and PD. We also examine the linkage of these neurodegenerative diseases to LSDs.  
2. Gangliosides stimulate amyloidogenesis in AD 
2.1 Aggregation of A in AD 
AD is a progressive degenerative disease of the brain with loss of memory and cognition, 
and is characterized by the two neuropathological hallmarks of senile plaques and 
neurofibrillary tangles. The former are mainly composed of aggregated A derived from 
amyloid precursor protein (APP), while the latter consist of paired helical filaments 
containing hyperphosphorylated tau(Yankner, 2000). 
It is well characterized that amyloidogenic A is generated by the consecutive cleavage of 
two proteases: - and -secretase(Selkoe, 2008). Consistent with biochemical studies 
demonstrating that A42 is more amyloidogenic compared to A40 and other Aforms, it 
has been shown genetically that increased A42 production is associated with inherited 
familial AD. In contrast, alternative cleavage of A at amino acid 17 by -secretase releases 
sAPP and excludes production of A. The predominant cleavage product is sAPP, 
serving to prevent production of A. 
The mechanism of neurotoxicity caused by A is incompletely understood. However, it is 
generally believed that aggregation of A results in formation of neurotoxic protofibrils and 
deposition of amyloid plaques(Yankner, 2000). Thus, factors regulating A aggregation and 
secretion are very important for the etiology of AD. 
2.2 Ganglioside interactions with A 
Considerable attention has been focused on the roles of gangliosides in the development of 
AD, since a number of in vitro studies have shown that GM1 ganglioside has a high affinity 
for A and accelerates A assembly, which leads to amyloid fibril formation. In this regard, 
Yanagisawa and Ihara reported that A adopts an altered conformation through binding to 
GM1 in brain, which subsequently facilitates the assembly of soluble A by acting as an 
endogenous seed, GAGM1-A(Fig. 2A)(Yanagisawa et al., 1995). Subsequently, 
Yanagisawa and colleagues developed a monoclonal antibody against purified GA from 
AD brain(Hayashi et al., 2004). Notably, the antibody inhibits A assembly in vitro through 
binding to GA and A. In addition, this antibody potently inhibits the assembly of A40 
and A42 in vitro. Furthermore, peripheral administration of Fab fragments of the antibody 
to transgenic mice expressing a mutant APP resulted in marked suppression of A 
deposition in the brain(Yamamoto et al., 2005b), thus suggesting that targeting of the 
endogenous seed could be a therapeutic strategy. Similar results have been obtained by 
other groups(Ariga et al., 2008; Choo-Smith et al., 1997; Matsuzaki and Horikiri, 1999; 
McLaurin and Chakrabartty, 1996). 
It is of particular interest that several A mutations in familial AD and hereditary cerebral 
amyloid angiopathy show distinct ganglioside affinity (Fig. 3A). A with the Arctic-type 
mutation (E22G) rapidly assembles in the presence of GM1, similarly to wild type 
A(Yamamoto et al., 2007). In contrast, A with the Dutch-type mutation (E22Q) assembles 
in the presence GM2 or GM3(Yamamoto et al., 2005a), and A with the Flemish-type 
mutation (A21G) assembles in the presence GD3(Yamamoto et al., 2005a). The pathological 
meaning of these phenomena is unknown. 
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Fig. 2. Mechanism of the stimulatory effects of GM1 on Aaggregation. 
A) A adopts an altered conformation through binding to GM1, which subsequently 
facilitates the assembly of soluble A by acting as an endogenous seed, GAGM1-A, 
leading to amyloid fibril formation.  
B) GM1 regulates the processing of APP by inhibition of -secretase and stimulation of - 
and/or -secretase activity, leading to increased secretion of A 
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Fig. 3. Affinity of gangliosides to amyloidogenic proteins. 
A) GM1, GM2/GM3 and GD3 stimulates assembly of E22G (Arctic-type mutation), E22Q 
(Dutch-type mutation) and A21G (Flemish-type mutation), respectively. 
B) GM1 strongly inhibits -synuclein fibrillation through binding to the NAC region, while 
channel formation by the DLB-linked E46K mutant of -synuclein is corrected by GM3. 
2.3 Regulatory roles of gangliosides on APP processing 
Besides a direct interaction with A gangliosides might also dysregulate APP processing 
associated with increased secretion of A, which couldultimately lead to enhanced 
aggregation of A(Fig. 2B). In support of this view, exogenous addition of GM1 in cultured 
neurons enhances A production in parallel with inhibition of sAPPsecretion(Zha et al., 
2004). These results suggest that GM1 regulates processing of APP by regulating the activity 
of secretases. There are two potential mechanisms for the inhibition of -secretase cleavage 
by GM1(Zha et al., 2004). First, stiffening of the membrane due to GM1 loading may 
decrease sAPP by inhibiting lateral movement and preventing the required contact 
between the enzyme and substrate. Second, since GM1 has been reported to have an 
inhibitory action on PKC, and sAPP is positively regulated by PKC activation, GM1 may 
inhibit sAPP secretion by inhibiting PKC activity. Both hypotheses require examination in 
further experimental work. 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
594 
It is also possible that GM1 could increase - and/or -secretase activity directly or 
indirectly. Indeed, since these secretases are thought to be localized to rafts, there might be 
as yet unknown biological functions underlying the connection between gangliosides and 
the secretases. Such a view may fit with a recent suggestion that amyloidogenic processing 
of APP depends on lipid rafts(Vetrivel and Thinakaran, 2010). Rafts are lateral assemblies of 
sphingolipids and cholesterol within the membrane. In this context, both gangliosides and 
cholesterol have been shown to bind to A and facilitate amyloid fibril formation(Kakio, 
2001). Taken together, these results suggest that processing of APP and generation of A can 
be modulated depending on the cellular content of gangliosides. 
2.4 Gangliosides and tau 
Currently, only a few reports have suggested a role of gangliosides in tau aggregation and 
NFT formation. McGeer and co-workers showed that the monoclonal antibody A2B5, which 
recognizes neuronal surface gangliosides, was strongly immunopositive for many NFTs, 
neuropil threads, and dystrophic neurites in AD(Tooyama et al., 1992). Similar strong 
immunoreactivities were observed in globose-type NFTs in cases of progressive 
supranuclear palsy cases and in Pick bodies in Pick's disease(Yasuhara et al., 1995). 
Takahashi et al. showed that fetal antigens such as the C-series gangliosides and 
microtubule-associated protein 5 immunostained dystrophic neurites of senile plaques, 
NFTs and neuropil threads in the cerebral cortex in AD brain, with similar immunostaining 
patterns to those of tau(Takahashi et al., 1991). These results suggest that regeneration or 
sprouting of neurons is ongoing in association with the re-induction of gene expression 
characteristics in the AD brain in the early stage of development. Further studies are 
required to investigate the interesting possibility that gangliosides bind with tau, and that 
this leads to formation of NFTs and other histopathologies in AD. 
2.5 Glial activation by gangliosides  
It has been well characterized that gangliosides are involved in regulation of glial 
activation(Cammer and Zhang, 1996). In this context, recent clinical reports show that 
reactive astrocytes have ganglioside GD3, unlike protoplasmic astrocytes, in patients with 
Creutzfeldt-Jakob disease and cerebral infarction(Kawai et al., 1999). Thus, it is likely that 
expression and localization of individual ganglioside subtypes in neurons and glia might 
change under the neurodegenerative conditions of AD and PD. 
3. Amelioration of the neuropathology of AD by gangliosides 
As described above, many studies have shown a role for gangliosides as stimulators of A 
amyloidogenesis in the early stage of AD. However, some studies have focused on the 
beneficial effects of gangliosides in treatment of AD. Svennerholm and Gottfries showed 
that the ganglioside content is reduced in early-onset or familial AD to 58-70% of that of 
control brains in gray matter and to 81% in frontal white matter(Svennerholm and Gottfries, 
1994). Notably, both GT1b and GQ1b were significantly decreased, while GD3 was 
increased, suggesting that metabolism of gangliosides may be dysregulated in AD. 
Furthermore, given the neurotrophic activities of gangliosides(Fusco et al., 1993), it seems 
likely that loss of gangliosides is correlated with the severity of AD. Based on this idea, 
Svennerholm performed intraventricular infusion of GM1 for AD brains and concluded that 
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GM1 treatment was effective for early onset AD, presumably through sequestration of 
Aby GM1(Svennerholm, 1994). More recently, Matsuoka et al. found that PS/APP mice 
administered peripherally with gelsolin or GM1 showed a substantial decrease in 
aggregated A40 and A42 in the brain. The result is reminiscent of the “sink effect” leading 
to reduction of A accumulation in the brain following passive immunization with anti-A 
antibodies(DeMattos et al., 2002). Based on this result, a novel therapeutic strategy was 
proposed using derivatives that are structurally related to gangliosides for specific targeting 
of pathogenic peptides in the periphery. 
4. Roles of gangliosides in the pathogenesis of PD and related disorders 
4.1 Synucleinopathies 
PD is a progressive degenerative disorder of dopaminergic neurons in the substantia nigra. 
PD manifests clinically as movement disorder, including tremor, rigidity, and gait 
disturbance, while non-motor type symptoms such as cognitive difficulties and sleep 
problems may arise in advanced stages(Hashimoto and Masliah, 1999; Trojanowski et al., 
1998). Because the pathology of PD is characterized by accumulation of -synuclein into 
inclusions called Lewy bodies in neurons, the disease is classified as a synucleinopathy. This 
spectrum of diseases also includes dementia with Lewy bodies (DLB), multiple system 
atrophy, and neurodegeneration with brain iron accumulation type I(Hashimoto and 
Masliah, 1999; Trojanowski et al., 1998). 
-Synuclein is a presynaptic protein of unknown function that is characterized by a 
natively unfolded structures, with highly conserved N-termini and divergent C-terminal 
acidic regions in the synuclein family of peptides, which has two other members: - and - 
synuclein(Hashimoto and Masliah, 1999). Importantly, -synuclein is distinct from other 
members of the synuclein family in that it possesses a highly hydrophobic central region 
that has been identified as a non-amyloid  component in Alzheimer disease(Ueda et al., 
1993). Since the discovery of the linkage of two missense mutations (A53T and A30P) to 
familial PD(Kruger et al., 1998; Polymeropoulos et al., 1997), numerous histopathological 
studies have shown that -synuclein fibrils are the major constituent in Lewy bodies and 
glial cell inclusions in synucleinopathies(Hashimoto and Masliah, 1999). Furthermore, 
another missense mutation, E46K, was recently identified for DLB(Zarranz et al., 2004). 
All the mutant proteins have a greater propensity for self-association and aggregation 
compared with wild-type -synuclein, suggesting that aggregation and protofibril 
formation of -synuclein has a causative role in stimulation of neurodegenerative 
disorders. 
4.2 Gangliosides bind with -synuclein 
Among various modulators, gangliosides may be particularly important as endogenous 
molecules that negatively regulate -synuclein aggregation. In this regard, Fink and 
colleagues investigated the interactions between various brain sphingolipids and -
synuclein and found that -synuclein specifically bound to ganglioside GM1(Martinez et al., 
2007). Furthermore, GM1 strongly inhibited -synuclein fibrillation, whereas total brain 
gangliosides, GM2, GM3, and asialo-GM1 had weak inhibitory effects on -synuclein 
fibrillation and induced some -helical structure(Martinez et al., 2007). Given the 
immunoreactivity of -synuclein in rafts, it is possible that -synuclein is recruited by GM1 
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to lipid raft regions in presynaptic membranes. In this context, perturbation of GM1/raft 
association could induce changes in -synuclein that contribute to the pathogenesis of PD. It 
is also noteworthy that GM3 may have a protective effect against channelopathy caused by 
-synuclein(Lashuel et al., 2002). The ability of -synuclein oligomers to form ionic channels 
was postulated as a channelopathy mechanism in human brain. Di Pasquale et al. identified 
a ganglioside-binding domain in the N-terminal region of -synuclein (aa 34-50) and 
showed that altered ion channel formation by the DLB-linked E46K mutant of -synuclein 
was corrected by GM3, but not by GM1 ganglioside(Di Pasquale et al., 2010). This result 
suggests that GM3, a minor brain ganglioside that is increasingly expressed with aging, 
might play a critical role in the neurotoxicity of -synuclein. It is also an intriguing 
possibility that gangliosides might have affinity for -synuclein mutations, as is the case for 
A mutations (Fig. 3B). 
4.3 Protective effects of gangliosides on lysosomal pathology of synucleinopathies 
Results in cell-free systems indicate that gangliosides may protect against synucleinopathies, 
and we have shown that changes in endogenous ganglioside levels affect lysosomal 
pathology in a cellular model of synucleinopathy(Wei et al., 2009a; Wei et al., 2007). In this 
work, DLB-linked P123H -synuclein neuroblastoma cells transfected with -synuclein were 
used as a model system because these cells have extensive formation of lysosomal inclusion 
bodies. Treatment of the cells with D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP), an inhibitor of glycosyl ceramide synthase, resulted in various features of 
lysosomal pathology, including compromised lysosomal activity, enhanced lysosomal 
membrane permeabilization, and increased cytotoxicity (Fig. 4). Consistent with these 
findings, expression levels of lysosomal membrane proteins, ATP13A2 and LAMP-2, were 
significantly decreased, and electron microscopy demonstrated alterations in the lysosomal 
membrane structures. Furthermore, accumulation of P123H -synuclein and -synuclein 
was significant in PDMP-treated cells because of the suppressive effect of PDMP on the 
autophagy pathway. Finally, the detrimental effects of PDMP on the lysosomal pathology 
were significantly ameliorated by addition of gangliosides to the cultured cells. These data 
suggest that endogenous gangliosides have protective roles against lysosomal pathology of 
synucleinopathies. 
4.4 Protective effects of gangliosides in an MPTP model 
There are few reports on the roles of gangliosides in synucleinopathies in vivo, but many 
studies have documented the beneficial effects of GM1 in drug-induced Parkinsonian 
models in animals, including those induced by treatment with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and 6-hydroxydopamine(Hadjiconstantinou et al., 1986; Jonsson 
et al., 1984). Mitochondrial dysfunction and oxidative stress are induced by these drugs, and 
it is possible that such oxidative stress is mitigated by gangliosides, similarly to suppression 
of oxidative stress induced by -synuclein aggregation. 
Despite the protective effects of gangliosides on drug-induced Parkinsonism, clinical trials 
of gangliosides for treatment of PD have been suspended because of the occasional 
development of an acute motor neuropathy (e.g. Guillain-Barré syndrome). Therefore, new 
derivatives of gangliosides are required that might efficiently sequester -synuclein without 
causing neuropathy and other side effects. 
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Fig. 4. Protective effects of gangliosides on lysosomal pathology in the DLB-linked cellular 
model. 
A) Immunofluorescence showed that the fluorescence of Lucifer Yellow in P123H -
synuclein-overexpressing B103 rat neuroblastoma cells transfected with A53T -synuclein 
was significantly increased by PDMP treatment (25 mol/L, 24 hrs) (b) compared to PDMP-
untreated cells (a). Ultrastructurally, some large electron-dense inclusions were composed of 
various types of giant autophagosomes (c, d), the membrane integrities of which were 
loosened by PDMP treatment (d). Scale bars: 10 m (a, b) or 1 m (c, d) 
B) Quantifications of Lucifer Yellow redistribution and LDH assay. In addition to P123H -
synuclein-overexpressing cells transfected with vector, wild-type -synuclein, or A53T -
synuclein, vector-transfected cells, wild-type -synuclein-overexpressing cells, and P123H -
synuclein-overexpressing cells were also analyzed. The number of Lucifer Yellow-positive 
cells in their cytosols at 48 hours of PDMP treatment was calculated as a percentage of the 
total number of cells (left panel). LDH assay was performed under the same conditions 
(right panel). Data are shown as means ± SD (n = 4). *P < 0.05, **P < 0.01 versus PDMP-
untreated cells. (Reprinted with permission from Am J Pathol, Wei et al, 2009, 174(5):1891-
1909.) 
5. Common pathology between neurodegenerative diseases and LSDs 
5.1 LSDs are associated with Lewy bodies and NFTs 
In the previous sections, we have described how gangliosides might be involved in the 
pathogenesis of neurodegenerative disorders such as AD and PD. Conversely, accumulating 
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evidence suggests that LSDs, including Gaucher disease, Sandhoff disease, Nieman-Pick C1 
disease, Tay-Sachs disease, metachromatic leukodystrophy, -galactosialidosis, and 
adrenoleukodystrophy, are associated with neuropathologies such as Lewy bodies and 
NFT(Saito et al., 2004; Suzuki et al., 2003; Suzuki et al., 2007). Furthermore, a recent study 
suggested that LSDs and neurodegenerative diseases are characterized by disorder of the 
autophagy-lysosomal pathway(Settembre et al., 2008; Tamboli et al., 2011). The overlapping 
pathology between the two disease spectrums might be attributable to direct and/or 
indirect interactions of gangliosides with amyloidogenic proteins, including Aand -
synuclein. However, the two disease types are currently treated as completely separate 
entities, which may mainly be due to the differences in onset age and clinical symptoms. 
5.2 Genetic link between neurodegenerative diseases and LSDs 
Emerging genetic evidence suggests that the distinction between the two disease types 
should be reconsidered. In this regard, several cohort studies of screening for the 
glucocerebrosidase gene in patients with PD and DLB have identified a high frequency of 
mutations(Hruska et al., 2006; Mitsui et al., 2009; Sidransky, 2004), suggesting that mutation 
of this gene is a risk factor for -synucleinopathies. Furthermore, the affinity of gangliosides 
for amyloidogenic proteins raises the intriguing possibility that the two disease spectrums 
are linked to each other more closely than previously thought. GM1 associates with the -
sheet structure of -synuclein (probably with the central NAC region), while GM3 
preferentially binds to the N-terminus of -synuclein. GM2 is abundantly accumulated in 
Sandhoff disease and Tay-Sachs disease, both of which have a Lewy body pathology(Suzuki 
et al., 2003), and this raises the question of how GM2 interacts with -synuclein. 
Furthermore, other sphingolipids may have affinity for -synuclein, given the accumulation 
of -synuclein in other types of LSDs. 
6. Conclusion 
In summary, gangliosides may be involved in the pathogenesis of AD, either by stimulating the 
seeding step of amyloidogenesis or through deregulation of the processing of APP. On the other 
hand, addition of gangliosides may be a useful strategy to sequester A, leading to suppression 
of extracellular deposits of A. In a similar context, the sequestering effects of gangliosides on -
synuclein may protect against an -synuclein pathology, such as channelopathy and 
intracellular lysosomal inclusion. Thus, currently available data suggest that gangliosides may 
act as a double-edged sword in neurodegenerative diseases such as AD and PD. 
However, information is still limited and further studies are required to elucidate the roles 
of gangliosides with respect to A and -synuclein, and also with tau and glial activation. 
Finally, the affinity of gangliosides to amyloidogenic proteins is an issue that may provide a 
key to solve as yet unknown mechanisms underlying common aspects of age-associated 
neurodegenerative diseases and LSDs.  
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